Cargando…
Camelid Single-Domain Antibodies: Promises and Challenges as Lifesaving Treatments †
Since the discovery of camelid heavy-chain antibodies in 1993, there has been tremendous excitement for these antibody domains (VHHs/sdAbs/nanobodies) as research tools, diagnostics, and therapeutics. Commercially, several patents were granted to pioneering research groups in Belgium and the Netherl...
Autor principal: | Arbabi-Ghahroudi, Mehdi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9100996/ https://www.ncbi.nlm.nih.gov/pubmed/35563400 http://dx.doi.org/10.3390/ijms23095009 |
Ejemplares similares
-
Camelid Single-Domain Antibodies: Historical Perspective and Future Outlook
por: Arbabi-Ghahroudi, Mehdi
Publicado: (2017) -
A Rational Engineering Strategy for Designing Protein A-Binding Camelid Single-Domain Antibodies
por: Henry, Kevin A., et al.
Publicado: (2016) -
Properties, production, and applications of camelid single-domain antibody fragments
por: Harmsen, M. M., et al.
Publicado: (2007) -
Enhancing Stability of Camelid and Shark Single Domain Antibodies: An Overview
por: Goldman, Ellen R., et al.
Publicado: (2017) -
Isolation and characterization of camelid single-domain antibodies against HER2
por: Hussack, Greg, et al.
Publicado: (2018)